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ABSTRACT  
Objectives: The therapy of the inflammatory bowel diseases is quite complex. A 
partial compliance increases the relapse probability and the health expenditure. The 
aim of the study is to correctly study the adherence to the therapy in a single centre 
eliminating the bias of a different relationship of trust with different doctors. 
Materials and methods: We conducted a blind prospective study on the adherence 
evaluated for mesalazine.  
Results: 376 patients were included in the final analysis. 57.4% of the patients never 
missed a single dose of mesalazine, 29.3% missed 1 or 2 doses, 7.4% missed 3 to 4 
doses, 5.9% missed more than 5 doses. A greater adherence among males (P = 
0.015) and, in ulcerative colitis, among the group with a disease duration of less than 
2 years compared to the one with a disease duration between 2 and 5 years (P = 
0.04) were found. In Crohn’s diseases, among the patients who had never 
undergone to surgical interventions, the adherence was 49.6%, compared to 51.9% 
among patients who underwent to one surgical resection and 78.6% among patients 
underwent to multiple surgical resections (P = 0.001).  
Conclusions: The factors influencing the adherence to the therapy are only partly 
related to the prescribed therapy, but also to factors affecting the patient life: to 
increase the adherence rate it would be necessary not only interventions on the 
posology but also the psychological support to the patient at the time of the visit.  
  
Keywords: adherence; Crohn’s disease; mesalazine; therapy; ulcerative colitis  
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Introduction 
Inflammatory bowel diseases (IBD) are a group of diseases of disimmune origin; the 
principal IBD are Crohns’ disease (CD) and ulcerative colitis (UC) [1]. 
    The therapy of the IBD is quite complex and depend from the disease’ behaviour 
and disease activity in the single patient: when the disease is active, the physician 
has to choose a therapy to induce disease remission and then establish a therapy to 
maintain the remission to reduce the number of the recurrences and so the 
progression of the disease [2]. When medical therapy is not sufficient, the patient will 
undergo to surgical resection, different depending on whether is affected by UC or 
CD [2]. Medical therapy of the IBD includes different drug category: aminosalicylates, 
corticosteroids, immunosuppressants, biologics. The efficacy of the aminosalicylates 
in the CD is controversial [3,4]. All the authors of the reviews and of the meta-
analysis agree in the efficacy of the aminosalicylates in the treatment of the UC [5,6]. 
In any case, the mesalazine has been shown to be a very safe drug in all meta-
analysis, with a very low rate of side effects [7]. Renal involvement is very rare and 
includes interstitial nephritis and nephrotic syndrome; patients with a pre-existing 
renal dysfunction are to be monitored in this regard [2]. The patients should take the 
therapy for all life, at least for the UC, in order to reduce the risk of disease relapse 
and, especially for patients with a colic localization, to reduce the risk of developing 
of colorectal cancer [2]. 
    The importance of taking the drugs at a minimum effective dose and for long 
periods raises questions about the patient's actual compliance with the prescription: 
failure to evaluate the compliance with the prescribed therapy can induce the 
clinician to raise the therapeutic level by considering the therapy prescribed falsely 
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ineffective. A partial compliance and even more the arbitrary suspension of the drug 
increase the relapse probability, the self-medication and so the health expenditure. 
Quantification of the compliance ranges from less than 40% [8] to about 93% [9] and 
correlations have been found with factors such as age, concomitant therapies for the 
same or other pathologies, level of education [9]. 
    However, to date there are few studies done in a single centre, with a large 
number of patients and with indication of therapy given by a single physician: this 
latter point is important because the study of the correct adherence to the therapy in 
a single centre dedicated to IBD would allow the patient's behaviour to be evaluated 
by eliminating the bias of a different relationship of trust with different doctors. 
    
Material and methods 
We conducted a blind (the questionnaire was anonymous) prospective study. 
Patients in therapy for IBD were randomly recruited at the outpatient clinic of the 
“San Giovanni Antica Sede hospital”, “AOU Città della Salute e della Scienza di 
Torino”, between June 1, 2016 and January 20, 2017.  
Inclusion criteria: 
- age higher than 15 years old 
- CD or UC diagnosed according to ECCO criteria [10,11] 
- in continuous therapy with oral mesalazine   
Exclusion criteria were: 
- previous surgeries for UC 
- lack of informed consent. 
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    The patients underwent to an anonymous questionnaire (see Supplementary data) 
to be completed alone at the time of the visit, with questions regarding the patient 
(sex, age, education level, comorbidity, drugs taken for other pathologies), the 
disease (type of IBD, years after the diagnosis, the time elapsed from the onset of 
the symptoms to the definitive diagnosis) and the therapy (type of therapy taken, the 
number of missed doses in the last two weeks, the concern for side effects, the 
decision to skip doses when they feel better, alternative therapies). The disease 
activity was evaluated by the physician. To complete the clinical characteristics of 
the included patients the data about, e.g., the specific biologic drug used were 
extracted in the aftermath by their medical records (a code has been assigned to 
every questionnaire). 
    Adherence to the therapy was evaluated for mesalazine in the two weeks prior to 
the visit [12]. It was decided to consider the patients adherent to the therapy if they 
reported to have never missed a single dose of mesalazine in the last two weeks and 
not-adherent to the therapy if they reported to have missed at least one dose of the 
mesalazine in the last two weeks.  
    The outcome was the discovery of factors correlated with the tendency of the 
patient to have a reduced compliance: sex, age, type of IBD, disease duration, the 
time between the onset of the symptoms and the diagnosis, the disease activity, the 
type of therapy, the number of drugs taken for IBD, the number of drugs taken for 
comorbidities, the concern about possible side effects of the therapy, the taking of 
alternative therapies, the education level, previous surgery for CD. 
    For the CD the disease activity was calculated with the Harvey-Bradshaw index 
[13], for the UC with the partial MAYO score [14].  
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Statistical considerations  
Regarding the univariate analysis, to analyse the categorical variables the Fisher’s 
exact test was used. For non-parametric variables, their normal distribution was 
tested with the D’Agostino-Pearson test. To compare the average of two 
independent samples the t-test for independent samples, if the data were normally 
distributed, were used, the non-parametric Mann-Whitney test, if the data were not 
normally distributed not even after a logarithmic transformation, were used. To test 
whether two variables were associated, in case the distribution of the two variables 
was normal, the correlation test was used, in case the distribution of the two 
variables was not normal, the Rank correlation test was used. Regarding the 
multivariate analysis the Cox proportional-hazards regression has been used. 
    The statistical significance level was set to 95%. 
    The statistical analysis was performed by using MedCalc software (version 
14.8.1). 
 
Ethical statement 
The work has been approved by the ethical committees of our institution and the 
subjects gave informed consent to the work. 
 
Results 
The questionnaire was administered at our tertiary centre to 523 patients: 147 
patients were excluded because they were not in continuous therapy with oral 
mesalazine (98) or because they did not complete part of the questionnaire (49). The 
clinical characteristics of the included patients are reported in Table 1. 
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Table 1 
 
    216 patients (57.4%) had never missed a single dose of mesalazine, 110 (29.3%) 
subjects had missed 1 or 2 doses of the therapy over the past two weeks, 28 
patients (7.4%) had missed 3 to 4 doses and 22 (5.9%) had missed 5 or more doses 
(Figure 1). 
 
Figure 1 
 
Univariate analysis 
The major adherence data for the whole IBD group and for CD and UC are 
presented in Table 2. 
 
Table 2. 
 
Since the subgroup of patients with IBDU was numerically weak (8 patients), it was 
decided to not compare this group with patients with CD or UC, but to consider these 
patients only in the analyzes of the whole population of 376 patients.   
    
Type of IBD 
Among UC patients, the adherence was 60.6% (89 adherents versus 58 not-
adherent patients), while the adherence was 55.6% (123 adherents versus 98 not-
adherent patients) in the CD group (P = 0.35). 
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Sex, age, education level 
The adherence to the therapy among all female patients in the study lower than 
among the male was 50.3% (P = 0.015) (Figure 2). 
 
Figure 2. 
 
Even in the group of CD patients the males were statistically significant more 
adherent (63.4%) than females (45%) (P = 0.006). Instead, in the group of UC 
patients the difference was not statistically significant (P = 0.6). 
   In the whole population (all the P were > 0.06), among CD patients (all the P were 
> 0.5), as well as among UC patients (all the P were > 0.2) the adherence’ rates 
were not affected by the age. 
   The school diploma did not influence the adherence to the therapy (t-test for trend 
P > 0.38).     
 
Disease duration, diagnostic delay 
Among the whole population, the adherence difference between the group with a 
disease duration between 6 and 10 years and the group with a disease duration 
between 11 and 15 years resulted statistically significant (P = 0.01) (Figure 3). 
 
Figure 3 
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In the group of patients with CD the difference between the adherence of the 
patients with disease duration between > 6 and 10 years and of the patients with 
disease duration between > 10 and 15 years was the closer to the statistical 
significance (P = 0.06). 
In the group of patients with UC, the adherence difference between the group with a 
disease duration of less than 2 years and the one with a disease duration between 2 
and 5 years resulted statistically significant (P = 0.04). 
    In the whole population the diagnostic delay did not influence the adherence (all 
the P were > 0.1), as well as in CD patients (all the P were > 0.07), and even less in 
UC (all the P were > 0.7). 
   Among the whole population (P = 0.82), CD patients (P = 0.88), as well as among 
UC (P = 0.9) the disease activity did not influence the adherence to the therapy. 
 
Number of medications and fear of side-effects 
Among patients with CD, 17.6% (39) reported that they used to miss some dose of 
the therapy if they felt better, while 82.4% (182) reported that they did not miss 
doses even during periods of subjective well-being. Among patients with UC, 17% 
(25) reported that they used to miss some dose of the therapy if they felt better, while 
83% (122) reported that they did not miss doses even during periods of subjective 
well-being. 
    The number of drugs for IBD did not influence the adherence to the therapy (in 
both tests the P was at least 0.1). 
   The number of other medications for other pathologies did not influence the 
adherence to the therapy (in each comparison the P was at least 0.47). 
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   The fear of side effects did not influence the adherence to the therapy (the 
adherence difference between the 3 groups was not statistically significant, t-test for 
trend P > 0.45). 
    The taking of not-prescribed did not influence the adherence to the therapy (P = 
0.44). 
     
Number of surgical resections in CD 
In CD patients, the adherence was statistically significant higher (P = 0.001) in the 
group in which patients underwent to multiple surgical resections compared to the 
other two groups. 
 
Multivariate analysis 
At multivariate analysis the data which have been confirmed to be statistically 
significantly related to the increase in the adherence were: 
- the males were more adherent to therapy than females in the whole population (P = 
0.03) and in the subpopulation of patients with CD (P = 0.01) 
- the higher adherence in the group with a disease duration between 6 and 10 years 
compared to the group with a disease duration between 11 and 15 years in the 
whole population (P = 0.03) 
 - in CD patients, the higher adherence (P = 0.003) in the group in which patients 
underwent to multiple surgical resections compared to the other two groups. 
 
Discussion 
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In our population the overall adherence resulted 57.4%: although it falls within the 
range of those published in the literature (11% - 86%) [12,16,17], the reason why it is 
much lower than that was found in some studies may result from the fact that our 
adherence definition is narrower (it was decided to consider the patients adherent to 
the therapy if they reported to have never missed a single dose of mesalazine in the 
last two weeks, while in other studies the patients are considered adherent even if 
they miss 1 or two doses [12,15,16]). 
   The first data reported to be statistically significantly related to the increase in the 
adherence was the male sex: in the general population, the males were more 
adherent to therapy than females (P = 0.015). This data was confirmed in the 
subpopulation of patients with CD (P = 0.006), while it was not true for subpopulation 
of UC patients (P = 0.6). 
Regarding the disease’ duration, in patients with UC the adherence difference 
occurred between the group diagnosed from less than 2 years and the group 
diagnosed between 2 to 5 years (statistically significant, P = 0.04), with an increase 
in the adherence between the first and the second group of the patients. In the 
patients with CD there seems to be a trend, not statistically significant (P = 0.06), in 
the reduction of the compliance among the group of patients with a disease that lasts 
from 5 to 10 years and the group of patients with disease that lasts from 11 to 16 
years. This observation is probably due to the fact that, in the patients with UC, the 
start of the therapy at the time of the diagnosis induces a rapid reduction of the 
symptoms (especially of the ematochezia, a symptom that greatly worries the 
patient), inducing in the patient the wrong thought to be "cured" and therefore 
causing less attention to the therapeutic regimen. Subsequently, due to the likely 
recurrence of the symptomatology with poor adherence to the therapy and the 
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consequent delivery of the patient to a third level centre, the patient compliance 
increases again and will not to decrease significantly anymore. 
The data about the disease' activity show that the compliance is not influenced by 
the phase of activity of the disease, as well as the number of the drugs taken for the 
IBD or other pathologies. 
Some characteristics of the patient independent from the disease such as their age, 
the education level seem to not affect the adherence to the therapy. 
For the first time in the literature, we found a statistically significant difference (P = 
0.001), in the patients with CD, in the compliance between the patients who 
underwent to surgical resection. The turning point in the adherence to the therapy 
seems to be between the group in which the patients underwent to one surgical 
resection and the group in which the patients underwent to multiple surgical 
resections. These data suggest that the likely patient's concern for further surgery 
may induce him to increase his adherence to the therapy. 
   In chronic diseases, especially if they have a chronic-relapsing course, as in IBD, 
the patient' adherence to the therapy is far from optimal [17]. 
This problem has been addressed by a few number of studies in the literature, 
through various means of evaluation of varying complexity and reliability. In one of 
the published studies [12], the objective was to compare three methods of evaluation 
of the adherence to the therapy in order to find the most representative but, at the 
same time, easy to perform. Unlike in our study, only barriers related to the drugs 
(the patient’ belief in the importance of maintenance therapy when asymptomatic, 
and their concerns about side effects) have been found. 
In the study of Delven et al. [15], the authors have identified, in a small sample (27 
patients, 78% with UC and 6 22% with CD), as possible obstacles to the adherence 
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to the treatment, factors such as: the concomitance of other priorities to be followed 
(many patients have reported as the workload or the breakage of the routine on 
vacation or on weekends may lead to forget to take the drugs), the fear for the social 
stigma resulting from the pathology, the need to go often to the pharmacy, the cost 
of the therapies, the concern for the side effects, the size and frequency with which 
the tablets should be taken and, finally, the belief that the therapy is not giving any 
benefit. Coenen et al. [16], instead, had identified, in 471 patients with IBD, as 
factors that decrease the adherence to the therapy: to be single, to be less than 40 
years old, a high instruction level and the therapy based on mesalazine; while, to be 
a self-owner worker seems to better the adherence. In no study has been analyzed a 
factor like the number of surgical resections in CD, and our is the first study that 
highlight the attention on female CD patients and on UC patients after the first 2 
years of diagnosis (the last two predictors of a weak adherence). 
     
Strengths and limitations 
A potential limitation of our study is that the overall adherence to therapy has been 
evaluated based on that of the adherence to mesalazine (but we did not inquire the 
dose, number of mesalamine tablets, that the patients were supposed to take). This 
choice was made because the mesalazine was considered the drug most easily 
"forgettable" by the patients and we considered significant even a single dose lost in 
a short period of two weeks. 
Another potential limitation of our study is that it was decided to consider the patients 
adherent to the therapy if they reported to have never missed a single dose of 
mesalazine in the last two weeks and non-adherent to the therapy if they reported 
having missed at least one dose of mesalazine in the last two weeks: this definition 
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of adherence to the therapy could seem to be strict, but the mesalazine is a drug that 
is usually taken throughout life, so to miss one dose in the last two weeks may be 
reasonably associated to miss more doses throughout life. Therefore, an adherence 
of 57% is probably even overestimated.  
Similar studies were present in the literature, but there are no studies with a so large 
number of patients included in a single centre and cared by a single physician (M. 
A.): this allowed us, for the first time in literature, to evaluate the patient’ behaviour 
by eliminating the confounding factor that a different relationship of trust with 
different doctors could have on patient’ compliance.  
    In conclusion, the study shows that the factors influencing the adherence to the 
therapy are only partly related to the pathology itself (incidence of surgical 
intervention and duration of illness) or to the prescribed therapy, but also to factors 
affecting the patient itself (sex, tendency to skip therapy if he feels better). For all 
these reasons, to increase the adherence rate to the therapy in patients with IBD, 
which is still too low, it would be necessary not only interventions on the drug' 
posology but also the psychological support to the patient at the time of the 
gastroenterological visit.  
In our view, in order to improve patient compliance, the doctor should tailor the 
therapy for each patient, reducing the number of tablets at the lowest effective dose 
and emphasizing to the patient the importance of following his therapeutic regimen. 
The optimization of the doctor-patient relationship in this context would have the role 
of improving the adherence to the therapy and, in turn, of reducing the risk of 
complications related to the disease and the health care costs.  
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Further studies of the adherence performed together with general practitioners would 
be useful to assess the actual patient’ adherence (through measurement of actual 
boxes of medication prescribed to the patient by his family doctor). 
 
Conflicts of Interest Statement 
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Table 1. The clinical characteristics of the included patients (n = 376) 
 
Disease, n (%) 
   CD 
   UC 
   IBD-U 
Sex, n (%) 
   Males 
   Females 
 
221 (58.8) 
147 (39.1) 
    8   (2.1)    
 
214 (57) 
162 (43) 
Age (years old), n (%) 
   < 20 
   20 - 30 
   31 - 50 
   51 – 70 
   > 70 
Disease duration (years), n (%) 
   < 2 
   2 - 5 
   6 - 10 
   11 – 15 
➢ 15 
Disease activity 
   remission 
   mild to moderate 
   severe 
 
    4   (1.2) 
  47 (12.1) 
152 (40.5) 
145 (38.7) 
  28   (7.5) 
 
  27   (7.2) 
  55 (14.5) 
  87 (23.3) 
  61 (16.2) 
146 (38.8) 
 
252 (67.1) 
  71 (18.8) 
  53 (14.1) 
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Drugs in addition to the mesalazine 
   azathioprine 
   adalimumab  
   prednisone 
 
  70 (18.6) 
  43 (11.4) 
  93 (24.7) 
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Table 2. Adherence for the whole inflammatory bowel disease group, Crohn’s 
disease and ulcerative colitis 
 
 
    
 
Sex 
• F 
• M 
Age 
• <=30 
• 31-50 
• 51-70 
• >70 
Disease 
duration 
(years) 
• <2 
• 2-5 
• 6-10 
• 11-15 
• >15 
Diagnostic 
Delay 
IBD  
(Adherent/ 
not-adherent) 
 
81/80 
135/80 
 
30/20 
77/75 
89/55 
20/10 
 
 
 
14/13 
35/20 
58/29 
28/33 
81/65 
 
 
 
CD  
(Adherent/ 
not-adherent) 
 
43/52 
80/46 
 
18/12 
47/47 
53/34 
5/5 
 
 
 
8/6 
16/13 
31/18 
16/21 
52/40 
 
 
 
UC  
(Adherent/ 
not-adherent) 
 
36/26 
53/32 
 
11/7 
29/27 
35/20 
14/4 
 
 
 
4/6 
19/6 
25/11 
12/11 
29/24 
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• <1 
• 1-5 
• >5 
Disease 
activity 
• severe 
• mild/ 
moderate 
• remission 
Number of 
drugs for IBD 
• 1 
• 2 
• 3 
Number of 
drugs for 
other 
diseases 
• 0 
• 1 
• 2 
• 3 
• 4 
• >=5 
144/119 
53/26 
19/15 
 
 
29/23 
43/29 
 
144/108 
 
 
77/73 
69/39 
69/49 
 
 
 
 
95/74 
47/41 
34/21 
12/8 
8/9 
20/7 
 
72/67 
39/18 
12/13 
 
 
14/13 
29/21 
 
80/64 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
71/50 
13/6 
5/2 
 
 
14/9 
13/7 
 
62/42 
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Fear of side 
effects 
• very 
worried 
• quite 
worried 
• slightly 
worried  
Not-
prescribed 
therapies 
• 0 
• >=1 
School 
diplomas 
• element. 
school 
• second. 
school 
• high 
school 
• degree 
Surgical 
resection 
 
 
102/84 
 
88/55 
 
26/21 
 
 
 
 
177/126 
39/34 
 
 
21/15 
 
62/35 
 
105/82 
 
28/28 
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• 0 
• 1 
• >=2 
62/63 
28/26 
33/9 
IBD = inflammatory bowel disease; CD = Crohn’s disease; UC = ulcerative colitis; F = female; M = male; 
element. = elementary; second. = secondary 
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Figure 1. Adherence to mesalazine therapy in the two weeks prior to the visit in 
patients affected by inflammatory bowel disease 
Figure 2. Sex and adherence to the therapy in the two weeks prior to the visit in 
patients affected by inflammatory bowel disease 
Figure 3. Influence of the disease duration on the therapy adherence in the two 
weeks prior to the visit in patients affected by inflammatory bowel disease 
 
